SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 16, 2004
SANGUI BIOTECH INTERNATIONAL, INC.
------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Colorado
-------------------------------------------------------------
(State or other jurisdiction of Incorporation or organization
000-21271 84-1330732
------------------------ ------------------------------------
(Commission File Number) (I.R.S. Employer Identification No.)
Alfred-Herrhausen-Str. 44, 58455 Witten, Germany
--------------------------------------------------
(Address of principal executive offices)(Zip Code)
011-49-2302-915-204
----------------------------------------------------
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Item 5. Other Events
PCT Patent to be granted by European Patent Office
--------------------------------------------------
According to an EPO confirmation letter to SanguiBioTech GmbH (a
Wholly-owned Subsidiary of Sangui BioTech International, Inc.) dated December
2003, the European Patent Office (EPO) is about to grant a PCT/EP patent
covering Sangui's combination of haemoglobin with an emulsion for external
applications. This is the first world wide patent to be granted out of a series
of four patent applications covering the external use of Sangui's artificial
oxygen carriers. Sangui BioTech GmbH has, in the meantime, submitted an
additional patent application covering an innovative comprehensive concept of
bio regeneration of the skin based on an enhanced oxygen supply.
New director joins board of Sangui BioTech Intentional, Inc.
------------------------------------------------------------
On December 16, 2003, the Board of Directors appointed Dr. Joachim
Fleing as a director of Sangui Biotech International, Inc. Dr. Fleing has been
an independent communications consultant since 2002. Prior to this he served as
a communications officer with a German software and integration company, having
acted as an account director with a PR firm and a scholar at Marburg University
in previous appointments.
The Board of Directors of Sangui BioTech International, Inc., now
consists of five directors:
Professor Wolfgang Barnikol, M.D., Ph.D. - also the President and CEO
of the company;
Professor Joachim Lutz, M.D.;
Dr. Christoph Ludz; Dr. Markus Volpers; and Dr. Joachim Fleing.
Sangui BioTech GmbH. Appoints Managing Director
-----------------------------------------------
On December 16, 2003, the Board of Directors also appointed Hubertus
Schmelz as new Managing Director of Sangui BioTech GmbH. The management of the
German subsidiary includes:
Hubertus Schmelz - Managing Director;
Professor Wolfgang Barnikol - Chief Scientific Officer; and
Dr. Martin Burow as Chief Operating Officer.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the Undersigned, thereunto duly authorized.
Sangui Biotech International, Inc.
(Registrant)
Date: February 4, 2004 /s/ Wolfgang Barnikol
---------------- ----------------------------------
By: Wolfgang Barnikol
Its: President, CEO and CFO